Gennex Laboratories Ltd
BSE:531739
Gennex Laboratories Ltd
BSE:531739
Price:
9.41
INR
10.06%
Market Closed
Market Cap:
₹2.3B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Gennex Laboratories Ltd
BSE:531739
|
IN |
|
Conduit Holdings Ltd
LSE:CRE
|
BM |
|
Pinnacle West Capital Corp
NYSE:PNW
|
US |
|
European Medical Solutions
XBRU:ALEMS
|
BE |
|
M
|
Malee Group PCL
SET:MALEE
|
TH |
|
Conagra Brands Inc
NYSE:CAG
|
US |
|
FLJ Group Ltd
NASDAQ:XHG
|
CN |
|
Daodaoquan Grain and Oil Co Ltd
SZSE:002852
|
CN |
|
Metcash Ltd
ASX:MTS
|
AU |
|
Advanced Braking Technology Ltd
ASX:ABV
|
AU |
|
Konoike Transport Co Ltd
TSE:9025
|
JP |
|
DHI Group Inc
NYSE:DHX
|
US |
|
Nongshim Holdings Co Ltd
KRX:072710
|
KR |
|
G
|
GORE German Office Real Estate AG
XETRA:GAG
|
DE |
|
P
|
Porvair PLC
LSE:PRV
|
UK |
|
National Standard (India) Ltd
BSE:504882
|
IN |
|
Hangzhou DPtech Technologies Co Ltd
SZSE:300768
|
CN |
|
Japan Real Estate Investment Corp
TSE:8952
|
JP |
Multiples-Based Value
The Multiples-Based Value of one
GENNEX
stock under the Base Case scenario is
hidden
INR.
Compared to the current market price of 9.41 INR,
Gennex Laboratories Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GENNEX Multiples-Based Value
LOCKED
Multiples Across Competitors
GENNEX Competitors Multiples
Gennex Laboratories Ltd Competitors
Gennex Laboratories Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Gennex Laboratories Ltd
BSE:531739
|
2.3B INR | 1.5 | 11.7 | 13.2 | 14.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD | 13.6 | 42.8 | 28.9 | 30.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.4 | 31.2 | 17.2 | 24.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.6 | 16.4 | 10.1 | 12.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161B USD | 2.6 | 20.7 | 7.9 | 10.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120B USD | 2.5 | 17 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
